Drugs / ARQ-234
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | atopic eczema | — | “Submitted Investigational New Drug Application (IND) for ARQ-234, a novel fusion protein for the potential treatment of patients with atopic dermatitis” arcutis.com ↗ “The Company submitted its IND for ARQ-234 in July 2025.” arcutis.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07453602 | Mar 2026 → Apr 2028 expected | atopic eczema | Arcutis Biotherapeutics, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-03 | Arcutis Biotherapeutics, Inc. | Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis arcutis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARQ-234 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07453602 ↗ |
| Route | Subcutaneous | “ARQ-234 subcutaneous injectable solution” NCT07453602 ↗ |